[{"orgOrder":0,"company":"Curis","sponsor":"ImmuNext Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Onvatilimab","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Curis","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ Curis"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"3-Aminopyrrolidine dihydrochloride","moa":"VISTA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Aurigene Discovery Technologies","highestDevelopmentStatusID":"9","companyTruncated":"Curis \/ Aurigene Discovery Technologies"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CI-8993","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CA-4948","moa":"Interleukin-1 receptor-associated kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CI-8993","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CA-4948","moa":"Interleukin-1 receptor-associated kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CA-4948","moa":"Interleukin-1 receptor-associated kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CA-4948","moa":"IRAK4 kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CA-4948","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IL-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IL-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IRAK4 kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IL-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ University of Florida"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IL-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IRAK4 kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Emavusertib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Emavusertib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Curis \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Emavusertib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Emavusertib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ University of Florida"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Emavusertib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Curis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : CA-4948 (emavusertib) is an IRAK4/FLT3/CLK inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with Refractory Primary Central Nervous System Lymphoma.

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 12, 2023

                          Lead Product(s) : Emavusertib,Ibrutinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Under the terms of the agreement, Curis will supply emavusertib and Merck will supply pembrolizumab & bear the costs for clinical study of the novel combination of CA-4948 (emavusertib) and pembrolizumab (anti-PD1) in metastatic melanoma.

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 05, 2023

                          Lead Product(s) : Emavusertib,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : University of Florida

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Curis intends to use the net proceeds from the offering on research and development of CA-4948 (emavusertib), an Oral, small molecule IRAK4 kinase inhibitor, being developed for the treatment of Leukemia.

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 06, 2023

                          Lead Product(s) : Emavusertib,Azacitidine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Cantor Fitzgerald & Co.

                          Deal Size : $15.1 million

                          Deal Type : Public Offering

                          blank

                          04

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : CA-4948 (emavusertib) is a triple target inhibitor (IRAK4, FLT3 and CLK), which is investiated for patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS).

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 06, 2023

                          Lead Product(s) : Emavusertib,Azacitidine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : With the partial hold, FDA is requesting additional data from the study, including data related to the death of R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of...

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 04, 2023

                          Lead Product(s) : Emavusertib,Azacitidine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Aurigene

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Emavusertib (CA-4948) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 30, 2022

                          Lead Product(s) : Emavusertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : CA-4948 (emavusertib) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 18, 2022

                          Lead Product(s) : Emavusertib,Azacitidine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : CA-4948 (emavusertib), is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 10, 2022

                          Lead Product(s) : Emavusertib,Azacitidine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : University of Florida

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : TakeAim Lymphoma data for the combination of CA-4948 (emavusertib) plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses.

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 04, 2022

                          Lead Product(s) : Emavusertib,Ibrutinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The data from TakeAim Leukemia study are consistent with our findings demonstrated CA-4948 (emavusertib) encouraging monotherapy activity in patients with R/R AML and MDS including importantly those with spliceosome and FLT3 mutations.

                          Brand Name : CA-4948

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 12, 2022

                          Lead Product(s) : Emavusertib,Ibrutinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank